Synapticure aims to provide neurodegenerative patients, starting with ALS, access to the best care while fueling the advancement of personalized treatments for every type of ALS. We do so by providing end-to-end clinical care using our telemedicine platform to guide patients through their entire care journey. We are devoted to helping patients, from guidance on care and insurance to providing the full spectrum of investigational and clinical testing to improve outcomes. Synapticure was built by leading patient and caregiver advocates alongside leading ALS clinicians, biotech executives and telemedicine executives to bring the ALS care and treatment experience into the 21st century, and is backed by the leading Venture funds and Angel investors in the remote health and life sciences space.